^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
...the NCCN panel recommends pembrolizumab as an adjuvant therapy option for patients with stage III disease…Cutaneous melanoma.
